PLOD2 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

PLOD2 Polyklonal Antikörper für FC (Intra)

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

FC (Intra)

Konjugation

CoraLite® Plus 647 Fluorescent Dye

Kat-Nr. : CL647-21214

Synonyme

PLOD2-Specific, EC:1.14.11.4, Lysyl hydroxylase 2, PLOD2/LH2, Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2

---

• 

  FC experiment of HeLa using CL647-21214

  1X10^6 HeLa cells were intracellularly stained with 0.2 ug CoraLite® Plus 647 Anti-Human PLOD2 (CL647-21214) (red), or 0.2 ug Isotype Control (blue). Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in FC (Intra): HeLa-Zellen

Empfohlene Verdünnung

• Durchflusszytometrie (FC) (INTRA): FC (INTRA) : 0.20 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL647-21214 bindet in FC (Intra) PLOD2 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: PLOD2 fusion protein Ag15614
• Vollständiger Name: procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
• Berechnetes Molekulargewicht: 758 aa, 85 kDa
• Beobachtetes Molekulargewicht: 85 kDa
• GenBank-Zugangsnummer: BC037169
• Gene symbol: PLOD2
• Gene ID (NCBI): 5352
• Konjugation: CoraLite® Plus 647 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 654 nm / 674 nm
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.09% sodium azide
• Lagerungsbedingungen: Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

PLOD2,also named as LH2, forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. It is a potential novel prognostic factor for HCC patients following surgery. Among the PLOD genes, PLOD2 contributes to cancer prognosis and angiogenesis. Several authors have reported that PLOD2 expression might provide prognostic information about malignant tumours such as glioblastoma. PLOD2 expression is a useful biomarker for the effects of antiangiogenic treatment for malignancy. (PMID:22098155). It has 2 isoforms produced by alternative splicing and seven glycosylation sites.This antibody is specific to PLOD2.